Three Boston Scientific Drug-Eluting Stent Trials Meet ESC Treatment Guidelines for Improving Patient Outcomes

(September 8, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that three of its drug-eluting stent clinical trials have been recognized as meeting the treatment guidelines of the European Society of Cardiology (ESC), which met this week in Stockholm. Boston Scientific